Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma

Immune checkpoint inhibitors (ICPi) targeting the PD-1/PD-L1 pathway have shown marked success in patients with advanced melanoma. However, 60–70% of patients fail to respond, warranting a therapeutic intervention that could increase response rates. We and others have shown that S-adenosylmethionine...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Ali Mehdi, Mikhael Attias, Niaz Mahmood, Ani Arakelian, Catalin Mihalcioiu, Ciriaco A. Piccirillo, Moshe Szyf, Shafaat Ahmed Rabbani
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2020-09-01
סדרה:	Frontiers in Oncology
נושאים:	DNA methylation melanoma S-adenosylmethionine anti-PD-1 immunity immune checkpoint inhibitors
גישה מקוונת:	https://www.frontiersin.org/article/10.3389/fonc.2020.01361/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!